Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARALEN HYDROCHLORIDE vs ALBENZA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising p H and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.
Albendazole is a benzimidazole carbamate that inhibits tubulin polymerization by binding to the colchicine site of β-tubulin, disrupting microtubule formation. This leads to impaired uptake of glucose and depletion of glycogen stores, resulting in immobilization and death of susceptible helminths.
Treatment of uncomplicated malaria due to chloroquine-sensitive Plasmodium species,Prophylaxis of malaria in areas with chloroquine-sensitive parasites,Extraintestinal amebiasis,Treatment of discoid lupus erythematosus (off-label),Treatment of rheumatoid arthritis (off-label)
FDA-approved: Hydatid disease (Echinococcus granulosus) and neurocysticercosis (Taenia solium).,Off-label: Ascariasis, trichuriasis, hookworm infections, enterobiasis, strongyloidiasis, cutaneous larva migrans, giardiasis, microsporidiosis, and other parasitic infestations.
Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.
400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis.
48-72 hours (terminal elimination half-life); prolonged to weeks with chronic dosing due to extensive tissue accumulation, especially in the liver, spleen, and melanin-containing tissues.
Terminal elimination half-life of albendazole sulfoxide (active metabolite) is 8-12 hours; albendazole itself has a very short half-life (<1 hour) due to extensive first-pass metabolism.
Hepatic metabolism via CYP2C8, CYP3A4, and CYP2D6 to desethylchloroquine and other metabolites.
Primarily metabolized by hepatic microsomal enzymes, specifically to albendazole sulfoxide (active metabolite) via CYP3A4 and possibly other CYP isoforms. Further metabolized to albendazole sulfone (inactive) and other metabolites.
Renal (~70% unchanged), with 10-20% in feces; biliary elimination is minor.
Primarily biliary/fecal (less than 2% renal as unchanged drug and metabolites; most eliminated via bile into feces as metabolites).
50-60%, primarily to albumin and α1-acid glycoprotein.
Albendazole: ~70% bound to plasma proteins (mainly albumin). Albendazole sulfoxide: ~70% bound.
50-100 L/kg; extensive tissue sequestration including erythrocytes, liver, spleen, and melanin-containing tissues like skin and retina.
Albendazole sulfoxide: 0.8-1.2 L/kg, indicating extensive tissue distribution including bile and CSF.
Oral: ~70-80% (variable due to first-pass metabolism); intravenous: 100%.
Oral: Poor bioavailability (~5-10%) of parent drug due to extensive first-pass metabolism; enhanced (up to 5-fold) with high-fat meal. Not administered parenterally.
Severe renal impairment (GFR <10 m L/min): reduce dose by 50% or increase dosing interval.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
Use with caution in patients with hepatic impairment; no specific dose adjustment guidelines available; contraindicated in severe hepatic disease or porphyria.
Contraindicated in patients with known cirrhosis (Child-Pugh C). For mild to moderate hepatic impairment (Child-Pugh A or B), monitor liver function; dose adjustment not established.
Prophylaxis: 5 mg base/kg orally once weekly (max 300 mg base). Treatment: 10 mg base/kg orally initially, then 5 mg base/kg at 6, 24, and 48 hours (max 600 mg base total).
For children ≥2 years: 400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis. For children <2 years: not recommended.
Start at lower end of dosing range due to increased risk of adverse effects (e.g., QT prolongation, retinal toxicity); monitor renal function.
No specific dose adjustment recommended; use with caution due to potential hepatic and renal decline. Monitor for adverse effects.
No FDA black box warning.
NOT FDA APPROVED FOR ANY INDICATION IN THE UNITED STATES. (Note: This warning applies as Albendazole is not FDA-approved for use in the US; however, it is marketed elsewhere. In the US, it is available under an investigational protocol or as a compounded product.)
Retinopathy and irreversible retinal damage with prolonged use or high doses; requires baseline and periodic ophthalmologic exams,QT prolongation and ventricular arrhythmias, especially with concomitant QT-prolonging drugs or electrolyte abnormalities,Severe hypoglycemia including loss of consciousness,Neuropsychiatric effects including psychosis and suicidal ideation,Hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency
Bone marrow suppression: Monitor blood counts regularly; risk of agranulocytosis, pancytopenia.,Hepatotoxicity: Elevation of liver enzymes; contraindicated in patients with hepatic disease or abnormal liver function tests.,Neurotoxicity: Risk of seizures, especially in neurocysticercosis due to inflammatory response to dying parasites.,Carcinogenicity: Long-term use associated with increased risk of tumors in animal studies.,Pregnancy: Category D (positive evidence of human fetal risk); avoid use in pregnant women or those likely to become pregnant.
Hypersensitivity to chloroquine or any 4-aminoquinoline,Pre-existing retinopathy or known maculopathy,Known G6PD deficiency (relative, use with caution),Concomitant use with strong QT-prolonging drugs (e.g., quinidine, procainamide)
Hypersensitivity to albendazole or benzimidazole compounds.,Pregnancy (Category D) and lactation.,Pre-existing hepatic disease or unexplained liver function test abnormalities.,Bone marrow depression or severe neutropenia.
Avoid grapefruit and grapefruit juice as they may increase drug levels and toxicity. Limit alcohol intake to reduce risk of liver toxicity. Administer with food to decrease gastrointestinal irritation. Avoid antacids containing aluminum or magnesium; separate by at least 4 hours.
Albendazole absorption is enhanced by fatty foods; a high-fat meal increases plasma concentration of the active metabolite albendazole sulfoxide by up to 5-fold. Avoid grapefruit juice as it may alter metabolism via CYP3A4 inhibition. Fatty meals are recommended to maximize efficacy.
Chloroquine hydrochloride crosses the placenta. First trimester: associated with increased risk of spontaneous abortion and congenital abnormalities (cochleovestibular and ocular) at high doses. Second and third trimesters: possible ototoxicity and retinal toxicity; use only for malaria prophylaxis or treatment when benefit outweighs risk.
Albendazole is contraindicated in pregnancy, especially during the first trimester. It has been shown to be embryotoxic and teratogenic in animals. In humans, there are reports of congenital malformations when used during pregnancy, including craniofacial defects and limb abnormalities. Use is not recommended in women who are or may become pregnant.
Chloroquine is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.3). Amounts are unlikely to cause adverse effects in nursing infants. The American Academy of Pediatrics considers chloroquine compatible with breastfeeding. Monitor infant for potential ocular effects.
Albendazole is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 0.1. Due to potential adverse effects in nursing infants (e.g., bone marrow suppression, hepatic effects), caution is advised. The manufacturer recommends discontinuing breastfeeding or the drug, taking into account the importance of the drug to the mother.
Increased volume of distribution and clearance during pregnancy may require higher doses for malaria prophylaxis (e.g., 400 mg base weekly) and treatment; therapeutic drug monitoring recommended for optimal dosing. No standard dose adjustment established; base dose on indication and clinical response.
No specific dosing adjustments for pregnancy are established. Use is contraindicated in pregnancy due to teratogenicity. If treatment is necessary, avoid during first trimester and use the lowest effective dose for the shortest duration under strict medical supervision. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered metabolism) may require therapeutic drug monitoring if available.
ARALEN HYDROCHLORIDE (chloroquine hydrochloride) is used for malaria prophylaxis and treatment, and for amebiasis. Monitor for retinal toxicity with long-term use; baseline and periodic ophthalmologic exams recommended. Caution in patients with hepatic disease, G6PD deficiency, or porphyria. May exacerbate psoriasis and myasthenia gravis. QT prolongation possible; avoid with other QT-prolonging drugs. Administer with food to reduce GI upset. For acute malaria, dose may be divided to improve tolerance. In severe malaria, use parenteral form with cardiac monitoring.
Albendazole is a broad-spectrum anthelmintic effective against intestinal and tissue nematodes, cestodes, and some protozoa. It is poorly absorbed orally; co-administration with a fatty meal significantly increases bioavailability (up to 5-fold). Monitor liver function tests periodically due to risk of hepatotoxicity. Contraindicated in pregnancy (category C) and in patients with known hypersensitivity. For neurocysticercosis, concomitant corticosteroids and antiepileptics are often required to manage inflammatory reactions. May cause bone marrow suppression; obtain CBC at baseline and periodically. Dose adjustment not needed in renal impairment but caution in hepatic impairment.
Take this medication exactly as prescribed; do not skip doses for malaria prophylaxis.,If vomiting occurs within 1 hour of a dose, contact your healthcare provider for instructions.,Report any vision changes, such as blurred vision or difficulty focusing, immediately.,Avoid alcohol and limit caffeine intake as they may increase gastrointestinal side effects.,Use effective contraception during treatment if you are of childbearing potential.,Do not take antacids or kaolin within 4 hours of this medication.,Seek medical attention if you experience signs of allergic reaction: rash, hives, swelling, or difficulty breathing.
Take with a high-fat meal to increase absorption.,Complete the full course of therapy even if symptoms improve.,Use effective contraception during treatment and for at least 1 month after the last dose.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, right upper quadrant pain.,May cause dizziness; avoid driving or operating machinery if affected.,Notify your healthcare provider if you experience persistent sore throat, fever, or unusual bleeding/bruising.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARALEN HYDROCHLORIDE vs ALBENZA, answered by our medical review team.
ARALEN HYDROCHLORIDE is a Antimalarial that works by Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising p H and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.. ALBENZA is a Anthelmintic that works by Albendazole is a benzimidazole carbamate that inhibits tubulin polymerization by binding to the colchicine site of β-tubulin, disrupting microtubule formation. This leads to impaired uptake of glucose and depletion of glycogen stores, resulting in immobilization and death of susceptible helminths.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARALEN HYDROCHLORIDE and ALBENZA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARALEN HYDROCHLORIDE is: Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.. The standard adult dose of ALBENZA is: 400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARALEN HYDROCHLORIDE and ALBENZA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARALEN HYDROCHLORIDE is classified as Category C. Chloroquine hydrochloride crosses the placenta. First trimester: associated with increased risk of spontaneous abortion and congenital abnormalities (cochleovestibular and ocular) . ALBENZA is classified as Category C. Albendazole is contraindicated in pregnancy, especially during the first trimester. It has been shown to be embryotoxic and teratogenic in animals. In humans, there are reports of . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.